Overview

* Guardant Health ( GH ) Q3 revenue grows 39% yr/yr, beating analyst expectations

* Adjusted loss per share for Q3 beats consensus, reflecting operational improvements

* Company raises 2025 revenue guidance to $965-$970 mln, indicating strong growth outlook

Outlook

* Guardant Health ( GH ) raises 2025 revenue guidance to $965-$970 mln, up from $915-$925 mln

* Company expects 2025 oncology revenue to grow 25% year-over-year

* Screening revenue for 2025 expected between $71-$73 mln, driven by Shield tests

Result Drivers

* ONCOLOGY TEST VOLUME - Co attributes 40% growth in oncology test volume to strong performance across Guardant360 Liquid, Tissue, and Reveal tests

* SCREENING REVENUE - Shield screening tests generated $24.1 mln in revenue, marking significant growth from $1 mln in prior year period

* STRATEGIC COLLABORATIONS - Co established partnerships with Quest Diagnostics and PathGroup to expand Shield access nationwide

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $265.20 $235.69

Revenue mln mln (20

Analysts

)

Q3 Beat -$0.39 -$0.76

Adjusted (11

EPS Analysts

)

Q3 EPS -$0.74

Q3 Beat -$48.30 -$98.59

Adjusted mln mln (10

Net Analysts

Income )

Q3 Beat -$45.50 -$55.01

Adjusted mln mln (12

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Guardant Health Inc ( GH ) is $70.00, about 0.6% above its October 28 closing price of $69.58

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)